Catapult Network welcomes Government’s Innovation Strategy and ambition to cement UK position as a world-leader in science, research and innovation

The Catapult Network is ready to play a key role in implementing the strategy and supporting industrial sectors to innovate.

Catapult Network Confirms Commitment to Equality, Diversity and Inclusion

The CEOs of all nine Catapults came together at a special event held in the High Value Manufacturing Catapult’s MTC in Coventry to sign the shared Inclusivity in Innovation Charter.

No code, no problem: Chief.AI and Medicines Discovery Catapult harness the power of AI for new pay as you go drug discovery platform

Chief.AI, in partnership with Medicines Discovery Catapult (MDC), has launched the first no-code, pay as you go, AI platform for drug discovery.

Medicines Discovery Catapult welcomes new scientific and people leaders

Medicines Discovery Catapult (MDC) is proud to announce an extension to its talented workforce.

MDC Seeks Buyer for Alderley Park Lighthouse Laboratory

MDC Lighthouse Lab Recognised for “Best COVID-19 Responder” at Prestigious Industry Awards

The Alderley Park facility received the award for its integral role in establishing the Lighthouse Laboratory network.

£13m Translational Research Facility in Infectious Disease to Bolster North West’s Status as International Powerhouse in Life Sciences

The UK’s centre for therapeutics innovation, Medicines Discovery Catapult (MDC), has received a £5 million grant to build a Translational Research Facility in Infectious Disease on its Alderley Park site.

Medicines Discovery Catapult CEO to Change in 2021

Chris Molloy, Chief Executive Officer of the Medicines Discovery Catapult will be stepping down in September 2021 after five years in the role.

Accelerated and more efficient drug discovery in psychiatry – the impetus behind a year of upcoming activity between the Psychiatry Consortium and BNA

Psychiatric drug discovery must be a truly collaborative process if it is to be successful.